Ocular Safety of Topical Naltrexone.

摘要

During the past year we have obtained approval from our institutional and University Conflict of Interest Committees, which limited the ability of Dr. Sassani to actively participate in data collection or interpretation in the study. In order to compensate for this reduction in effective researchers, Dr. Esther Bowie, an Ophthalmologist on the faculty of our Department of Ophthalmology, will assist Dr. David Liang in performing the clinical studies and data collection. To date we have completed our first cohort of 4 volunteers at the once daily, 1 x 10-6 dosage, of topical Naltrexone in Vigamox eyedrops in one eye of each volunteer. No untoward side effects were noted in this group of volunteers. We also have recruited and treated three patients for the second cohort who have completed the treatment schedule. We need to recruit one more volunteer for this cohort and complete the other three cohorts. We are committed to completing the study, and have requested a one year extension of the grant period with no additional funds in order to complete our study.